Acorda Therapeutics, Inc.
OTC PK
| Weiss Ratings | - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.43 | |||
| Price History | - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | -64.50% | |||
| 60-Day Total Return | -96.73% | |||
| 90-Day Total Return | -97.39% | |||
| Year to Date Total Return | -97.15% | |||
| 1-Year Total Return | -97.27% | |||
| 2-Year Total Return | -96.32% | |||
| 3-Year Total Return | -99.51% | |||
| 5-Year Total Return | -99.97% | |||
| 52-Week High % Change | -97.66% | |||
| 52-Week Low % Change | 70.40% | |||
| Price | - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $18.21 | |||
| 52-Week Low Price | $0.25 | |||
| 52-Week Low Price (Date) | Apr 12, 2024 | |||
| 52-Week High Price (Date) | Aug 07, 2023 | |||
| Valuation | - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | -- | |||
| Enterprise Value | -- | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -203.87 | |||
| Earnings Per Share Growth | 118.11% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.00 | |||
| Price/Book (Q) | 0.00 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.43 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -- | |||
| Market Cap Category | -- | |||
| Dividends and Shares | - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.24M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 914 347 4300 | |||
| Address | 2 Blue Hill Plaza Pearl River, NY 10965 | |||
| Website | www.acorda.com | |||
| Country | United States | |||
| Year Founded | 1995 | |||
| Profitability | - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -19.77% | |||
| Profit Margin | -214.95% | |||
| Management Effectiveness | - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -5.77% | |||
| Return on Equity | -- | |||
| Income Statement | - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 117.63M | |||
| Total Revenue (TTM) | 117.63M | |||
| Revenue Per Share | $94.71 | |||
| Gross Profit (TTM) | 97.20M | |||
| EBITDA (TTM) | 8.40M | |||
| EBIT (TTM) | -23.26M | |||
| Net Income (TTM) | -252.85M | |||
| Net Income Avl. to Common (TTM) | -252.85M | |||
| Total Revenue Growth (Q YOY) | 20.70% | |||
| Earnings Growth (Q YOY) | -1,237.61% | |||
| EPS Diluted (TTM) | -203.87 | |||
| EPS Diluted Growth (Q YOY) | -2,105.20% | |||
| Balance Sheet | - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 29.98M | |||
| Cash Per Share (Q) | $24.14 | |||
| Total Current Assets (Q) | 74.79M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -157.96M | |||
| Current Ratio (Q) | 0.328 | |||
| Book Value Per Share (Q) | -$127.17 | |||
| Total Assets (Q) | 108.53M | |||
| Total Current Liabilities (Q) | 227.77M | |||
| Total Debt (Q) | 190.90M | |||
| Total Liabilities (Q) | 266.48M | |||
| Total Common Equity (Q) | -157.96M | |||
| Cash Flow | - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -264.00K | |||
| Cash from Financing (TTM) | -- | |||
| Net Change in Cash (TTM) | -14.06M | |||
| Levered Free Cash Flow (TTM) | 20.14M | |||
| Cash from Operations (TTM) | -13.98M | |||
